
- /
- Supported exchanges
- / US
- / NKTR.NASDAQ
Nektar Therapeutics (NKTR NASDAQ) stock market data APIs
Nektar Therapeutics Financial Data Overview
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Nektar Therapeutics data using free add-ons & libraries
Get Nektar Therapeutics Fundamental Data
Nektar Therapeutics Fundamental data includes:
- Net Revenue: 87 248 K
- EBITDA: -136 622 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.19
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nektar Therapeutics News

Why Nektar Therapeutics Stock Dived by 3% Today
Key Points The company announced it closed its latest capital-raising effort. This took the form of a nearly 5-million strong, secondary share issue. Nektar Therapeutics(NASDAQ: NKTR) saw its stock ...


Why Nektar Therapeutics Stock Dived by 3% Today
Key Points The company announced it closed its latest capital-raising effort. This took the form of a nearly 5-million strong, secondary share issue. 10 stocks we like better than Nektar Therapeutics...

Top Midday Decliners
Nektar Therapeutics (NKTR) slid 4.5% on Thursday after the biopharmaceuticals firm overnight said it PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...

Nektar Therapeutics stock dips after pricing $100M stock offering
* Nektar Therapeutics (NASDAQ:NKTR [https://seekingalpha.com/symbol/NKTR]) shares slipped over 3% premarket on Tuesday after the biotechnology company priced a stock offering to raise around $100M. ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.